If generics win the appeal, what does JT do with the US sales force?
Pay them a generous severance to go away? AMRN paid out money to Kowa
for them to go away...Who's bright idea was it to partner with them
to begin with? My guess is JT. To bad some people don't get it that
little companies trying to sell prescription medications just do not
get the ob done...especially for a low cost-high volume product.
If the US is lost to generics then Europe is AMRN's best hope. Should
JT decide to GIA there or JV it will not end well for AMRN investors.
For the sake of Cardiovascular patients, JT, get AMRN into the hands
of BP...at least they would have an adequate sales force and some
professional management. JT needs to sell the company or find someone
competent to do get that job done!
News 
Market Data 
Discover 
